甲磺酸伊马替尼的临床应用  

Clinical application of imatinib mesylate

作　　者：丁倩倩[1] 陈勤奋[1] 

机构地区：[1]复旦大学附属华山医院血液科,上海200040

出　　处：《上海医药》2013年第3期5-9,共5页Shanghai Medical & Pharmaceutical Journal

摘　　要：甲磺酸伊马替尼(imatinib mesylate/Gleevec,格列卫)是第一个被美国FDA批准上市的酪氨酸激酶抑制剂,已先后被写入慢性髓性白血病、胃肠道间质肿瘤、急性淋巴细胞白血病和黑色素瘤的国内、外治疗指南或共识。本文就此进行介绍,以期为该药的临床应用提供参考意见。Imatinib mesylate is the first generation of tyrosine kinase inhibitor approved by U.S. FDA for marketing. Its application was written in guidelines or consensuses for treating chronic myeloid leukemia, gastrointestinal stromal tumors, acute lymphoblastic leukemia and melanoma in succession at home and abroad. This article introduces the imatinib mesylate in guidelines or consensuses in order to provide reference information for clinical practice.

关 键 词：甲磺酸伊马替尼 酪氨酸激酶抑制剂 慢性髓性白血病 胃肠道间质肿瘤 急性淋巴细胞白血病 黑色素瘤 

分 类 号：R96[医药卫生—药理学]